The objective of this study was to compare the minimum inhibitory concentrations of antimicrobials included in a commercial broth microdilution panel among Gram-positive pathogens that caused non-severe clinical mastitis on three Michigan dairy farms. Duplicate quarter milk samples were collected from eligible quarters of cows enrolled in a randomized clinical trial, cultured in a university laboratory, and identified using MALDI-TOF. Etiologies were grouped by genus as Enterococcus species (n = 11), Lactococcus species (n = 44), non-aureus Staphylococcus species (n = 39), or Streptococcus species (n = 25). Minimum inhibitory concentrations (MICs) were determined using the mastitis panel of a commercially available broth microdilution test. In vitro susceptibility was determined using approved guidelines and included breakpoints for mastitis pathogens, or when not available, breakpoints from other species. Most isolates were inhibited at or below breakpoints that demonstrated in vitro susceptibility. The proportions of susceptible isolates varied among pathogens for pirlimycin, penicillin, and tetracycline. The greatest proportion of resistance was observed for pirlimycin, tetracycline, and sulfadimethoxine. Survival analysis was performed to evaluate differences in MICs among pathogen groups. MIC values varied among pathogens for ceftiofur, cephalothin, erythromycin, penicillin, pirlimycin, and tetracycline. However, nearly all isolates were susceptible to ceftiofur and cephalothin, indicating that pathogen differences in MIC are not likely clinically relevant, as these are the two most commonly administered mastitis treatments in the United States. While differences in vitro susceptibility were observed for some antimicrobials, susceptibility was high to cephalosporin-based IMM treatments that are most commonly used and did not vary among pathogens.
Automated monitoring devices have become increasingly utilized in the dairy industry, especially for monitoring or predicting disease status. While multiple automated monitoring devices have been developed for the prediction of clinical mastitis (CM), limitations in performance or applicability remain. The aims of this study were to (1) detect variations in reticuloruminal temperature (RRT) relative to an experimental intramammary challenge with Streptococcus uberis and (2) evaluate alerts generated automatically based on variation in RRT to predict initial signs of CM in the challenged cows based on severity of clinical signs and the concentration of bacteria (cfu/mL) in the infected quarter separately. Clinically healthy Holstein cows without a history of CM in the 60 d before the experiment (n = 37, parity 1 to 5, ≥120 d in milk) were included if they were microbiologically negative and had a somatic cell count under 200,000 cells/mL based on screening of quarter milk samples 1 wk before challenge. Each cow received an intra-reticuloruminal automated monitoring device before the trial and was challenged with 2,000 cfu of Strep. uberis 0140J in 1 rear quarter. Based on interrupted time series analysis, intramammary challenge with Strep. uberis increased RRT by 0.54°C [95% confidence interval (CI): 0.41, 0.66] at 24 h after the challenge, which remained elevated until the end of the study. Alerts based on RRT correctly classified 78.3% (95% CI: 65.8, 87.9) of first occurrences of CM at least 24 h in advance, with a sensitivity of 70.0% (95% CI: 50.6, 85.3) and a specificity of 86.7% (95% CI: 69.3, 96.2). The accuracy of CM for a given severity score was 90.9% (95% CI: 70.8, 98.9) for mild cases, 85.2% (95% CI: 72.9, 93.4) for moderate cases, and 92.9% (95% CI: 66.1, 99.8) for severe cases. Test characteristics of the RRT alerts to predict initial signs of CM improved substantially after bacterial count in the challenged quarter reached 5.0 log10 cfu/mL, reaching a sensitivity of 73.5% (95% CI: 55.6, 87.1) and a specificity of 87.5% (95% CI: 71.0, 96.5). Overall, the results of this study indicated that RRT was affected by the intramammary challenge with Strep. uberis and the RRT-generated alerts had similar accuracy as reported for other sensors and algorithms. Further research that includes natural infections with other pathogens as well as different variations in RRT to determine CM status is warranted.
1 September 2020 in Veterinary Immunology and Immunopathology
Summary: Nonsevere clinical mastitis identified as gram-positive using on-farm culture was caused by a wide range of pathogens. The primary pathogens identified on these farms were Lactococcus species. When comparing the bacteriological cure between the 3 different antimicrobial treatments and no treatment, bacteriological cure did not vary between the treated and controls 21 days after case detection. Cows with a greater parity and a history of subclinical mastitis before the enrolled case had reduced odds of bacteriological cure at day 21.
Streptococcus uberis is a common mastitis pathogen that lacks an effective vaccine in the United States and often requires antibiotic therapy. Supplementation of feed with Saccharomyces cerevisiae fermentation products (SCFP) has been associated with decreased SCC in dairy cows. The objective of this randomized clinical trial was to evaluate the effect of oral supplementation with SCFP on clinical and production outcomes in lactating dairy cows in response to intramammary challenge with Streptococcus uberis. Healthy cows (n = 42; parities 1-5; >120 DIM) were enrolled if their pretrial test day SCC was <200,000 cells/mL and they had no history of clinical mastitis in the preceding 60 d. Four cohorts of cows were blocked based on bovine leukemia virus infection status, parity group, milk yield, and DIM then randomly pre-assigned to receive a challenge in one quarter before being assigned to receive a treatment or control diet during a 45-d prechallenge phase, 5- to 7-d challenge phase, and 45-d postchallenge phase. Diets of cows assigned to treatment were top-dressed with 19 g/d SCFP for 45 d, and the control cows received 19 g/d of ground corn. During the prechallenge phase, quarter milk samples were collected weekly and used to determine SCC and IMI. Cows that did not develop IMI during the prechallenge phase (n = 37) were challenged with ∼2,000 cfu of S. uberis 0140J in one rear mammary gland; quarter milk samples were collected daily until antibiotic treatment (d 5 or 7) and data collection continued for another 45 d. Statistical analyses were performed using linear mixed models. Supplementation with SCFP did not affect DMI, milk production, or milk components during the prechallenge, challenge, or postchallenge phases. During the challenge week, there was no effect of SCFP on number of colonies of S. uberis or SCC in milk. The mean time (± SE) from intramammary challenge with S. uberis until onset of clinical mastitis was 3.88 ± 0.42 d and 4.84 ± 0.44 d for cows in the control group and SCFP treated groups, respectively. The mean days to bacteriological cure were 25.9 ± 3.5 (control cows) and 22.5 ± 3.1 (SCFP treated). As compared with values in control cows, supplementation with SCFP did not affect milk yield, DMI, or SCC of cows that received an intramammary challenge with S. uberis 0140J. Interestingly in a subset of animals that were infected with bovine leukemia virus, but not lymphocytic, before challenge supplementation with SCFP increased DMI 1.3 kg ± 0.6 and increased milk production by 2.3 ± 0.9 kg/d. This study was performed using a challenge model and a single pathogen type, future studies focusing on naturally occurring mastitis may be of value.